Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.5, Iss.2, 2006-03, pp. : 303-312

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment with irinotecan plus cisplatin has a similar survival benefit to etoposide plus cisplatin in patients with extensive-stage small cell lung cancer

Inpharma, Vol. 1, Iss. 1540, 2006-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients

By Rossi Antonio Maione Paolo Gridelli Cesare

Expert Opinion on Drug Safety, Vol. 4, Iss. 6, 2005-11 ,pp. : 1051-1067

Informa Healthcare

Access to resources Recommend Favorite

Pemetrexed for the treatment of non-small cell lung cancer

By Genova Carlo

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 11, 2013-08 ,pp. : 1545-1558

Informa Healthcare

Access to resources Recommend Favorite

Vandetanib for the treatment of non-small-cell lung cancer

By Wong Hui-li de Boer Richard H

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 14, 2011-10 ,pp. : 2271-2278

Informa Healthcare

Access to resources Recommend Favorite

Vinorelbine in the Treatment of Non-Small Cell Lung Cancer

Current Medicinal Chemistry, Vol. 9, Iss. 8, 2002-04 ,pp. : 879-891

Bentham Science Publishers

Access to resources Recommend Favorite